Lab Information

Waqqas Afif (MD/MSc)

Investigator
Clinical Research Unit
Department of Medicine (McGill)

Research Profile

 Fundamental: 0%
 Clinical: 20%
 Epidemiology: 80%
 Evaluation: 0%
 This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords

Inflammatory bowel disease • Crohn's disease • ulcerative colitis • biologic medications • therapeutic drug monitoring

Research Interests

My research focuses on the safety and efficiency of biologic medications in the treatment of IBD. I am interested in the use of therapeutic drug monitoring to optimize the treatment of IBD patients on biologic medications.


Team Members

Name Position

Latest Publications

  1. Lichtenstein, G. R., Allegretti, J. R., Rubin, D. T., Magro, F., Bressler, B., Panés, J., Afif, W., Samaan, M. A., Ye, B. D., Yarandi, S., Germinaro, M., Shipitofsky, N., Miao, Y., Zhang, H., Dignass, A., Sands, B. E., Hisamatsu, T. & Peyrin-Biroulet, L. (2026). Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study. The American journal of gastroenterology.
  2. Shahrokh, D. K., Vender, R. B., Lynde, C. W., Rao, J., Afif, W., Steinhart, A. H., Narula, N., Sutton, E., Thorne, C. & Bessette, L. (2026). Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN). Rheumatology and therapy.
  3. Niyigena, E., Hoffert, Y., Afif, W., Pedicelli, A., Roblin, X., Hanžel, J., Papamichael, K., Kobayashi, T., Elens, L., Wang, Z., Ferrante, M., Verstockt, B., Vermeire, S., Vande Casteele, N., Battat, R. & Dreesen, E. (2026). Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis. Journal of Crohn's & colitis, vol. 20.
  4. Moura, C. S., Etingin, A., Lukusa, L., Singh, H., Narula, N., Targownik, L. E., Leung, Y., Zezos, P., Polewiczowska-Nowak, B., Afif, W. & Bernatsky, S. (2026). Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars. World journal of gastroenterology, vol. 32, p. 114580.
  5. Kritzinger, J., Candel, I., Kotrri, G., Nadeem, H., Afif, W., Bitton, A., Wild, G., Bessissow, T. & Lakatos, P. L. (2025). Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. World journal of gastroenterology, vol. 31, p. 114355.
  6. Avinashi, V., Gupta, M., Payne, B. A., Amhaz, H., Temirova, A. T., Afif, W., Ashok, D., Barkey, J., Burnett, D., Bush, J. W., Cameron, S., Carr, S., El Demellawy, D., Erdle, S., Huynh, H. Q., Griffin, J., Grover, S. C., Grzywacz, K., Jeimy, S., Ko, H. H., Lacuesta, G., Marcon, M., Mayrand, S., Petropolis, H., Rodrigues, D., Sherlock, M., Song, C., Tardio, N., Vander Leek, T. K., Vurzinger, M., Williams, B., Xenodemetroupolous, T., Ma, C. & Chan, E. S. (2025). Recommendations for the diagnosis and management of eosinophilic esophagitis in adults and children in Canada: a Delphi consensus project. Journal of the Canadian Association of Gastroenterology, vol. 8, p. 207-227.
  7. Oketola, B., Bernatsky, S., Lukusa, L., Moura, C. S., Neville, A., Leung, Y., Narula, N., Afif, W., Birck, M. G., Zezos, P., Singh, H. & Canadian IBD Research Consortium (2026). Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar anti-Tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-World Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC Registry. Gastro hep advances, vol. 5, p. 100821.
  8. Pedicelli, A., Bessissow, T. & Afif, W. (2025). Personalizing IL-23 Inhibitor Therapy in IBD: Current Evidence and Future Directions in Therapeutic Drug Monitoring and Dose Optimization. Journal of clinical medicine, vol. 14.
  9. Avinashi, V., Gupta, M., Payne, B. A., Amhaz, H., Temirova, A. T., Afif, W., Ashok, D., Barkey, J., Burnett, D., Bush, J. W., Cameron, S., Carr, S., Demellawy, D. E., Erdle, S., Huynh, H. Q., Griffin, J., Grover, S. C., Grzywacz, K., Jeimy, S., Ko, H. H., Lacuesta, G., Marcon, M., Mayrand, S., Petropolis, H., Rodrigues, D., Sherlock, M., Song, C., Tardio, N., Vander Leek, T. K., Vurzinger, M., Williams, B. A., Xenodemetropoulos, T., Ma, C. & Chan, E. S. (2025). Recommendations for the diagnosis and management of eosinophilic esophagitis in adults and children in Canada: a Delphi consensus project. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, vol. 21, p. 47.
  10. Ongay, J., Candel, I., Bitton, A., Afif, W., Bessissow, T. & Lakatos, P. L. (2025). Case Report: Secukinumab (Interleukin-17 Inhibitor) and Ulcerative Colitis Flare - the Double-Edged Sword. Case reports in gastroenterology, vol. 19, p. 637-643.
More on PubMed 



See also

Card image
Talat
Bessissow


See profile
Card image
Peter
Lakatos


See profile
Card image
Alain
Bitton


See profile
Card image
Sasha
Bernatsky


See profile
Card image
Paul
Brassard


See profile
Card image
Évelyne
Vinet


See profile